← Back to Search

Radiation Therapy + Bevacizumab for Recurrent Brain Cancer

N/A

Waitlist Available

Led By Susan L McGovern

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patient must have received one and only one previous course of radiation to the brain, delivered at 1.5 - 2.5 Gy/fraction, one fraction per day

Lansky/Karnofsky performance status score of 50-100

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 3.5 years

Awards & highlights

Study Summary

This trial is testing different ways of giving radiation therapy to patients with brain tumors that have come back after previous treatment. The goal is to find the best way to give the therapy with the least amount of side effects.

Who is the study for?

This trial is for patients with brain tumors that have returned after previous radiation therapy. Eligible participants must have had only one prior round of radiation, may have undergone surgery before re-radiation, and should not be pregnant or have recurrent diffuse intrinsic pontine glioma (DIPG). They need a performance status score of 50-100 and recent imaging showing recurrent disease.Check my eligibility

What is being tested?

The study tests the side effects and optimal dose of re-administering radiation therapy to treat recurring brain tumors. It explores whether different methods of delivering radiation can more effectively kill tumor cells. Bevacizumab may also be used at the treating neuro-oncologist's discretion.See study design

What are the potential side effects?

Potential side effects include those typically associated with radiation therapy such as fatigue, skin irritation, hair loss in the treated area, headaches, nausea, and potential damage to surrounding healthy brain tissue.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have had one round of brain radiation at a specific dose.

Select...

I can do most activities but may need help.

Select...

My recent scans show signs of my brain disease coming back.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 3.5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 3.5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3.5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Highest grade of central nervous system (CNS) necrosis

Secondary outcome measures

Imaging changes as measured by Advanced Brain Tumor Imaging (ABTI)

Incidence of acute and late toxicities

Overall survival (OS) time

+2 more

Other outcome measures

Symptom burden

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Arm I (conventional fractionation)Experimental Treatment2 Interventions

Patients undergo radiation therapy with conventional fractionation and dose constraints. Treatment continues for up to 6 weeks in the absence of disease progression or unacceptable toxicity.

Group II: Arm II (conventional fractionation, bevacizumab)Active Control3 Interventions

Patients undergo radiation therapy with conventional fractionation and dose constraints. Patients also receive bevacizumab concurrently at the discretion of the treating neuro-oncologist. Treatment continues for up to 6 weeks in the absence of disease progression or unacceptable toxicity.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Radiation Therapy

2017

Completed Phase 3

~7250

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor

2,971 Previous Clinical Trials

1,787,197 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,658 Previous Clinical Trials

40,924,507 Total Patients Enrolled

Susan L McGovernPrincipal InvestigatorM.D. Anderson Cancer Center

1 Previous Clinical Trials

Media Library

Radiation Therapy Clinical Trial Eligibility Overview. Trial Name: NCT02698254 — N/A

$Brain Tumor Research Study Groups: Arm I (conventional fractionation), Arm II (conventional fractionation, bevacizumab)$

Brain Tumor Clinical Trial 2023: Radiation Therapy Highlights & Side Effects. Trial Name: NCT02698254 — N/A

Radiation Therapy 2023 Treatment Timeline for Medical Study. Trial Name: NCT02698254 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could you elucidate on the extent of research that has been done in regards to Radiation Therapy?

"At present, 355 radiation therapy studies are in progress with 89 trials having reached Phase 3. With the majority of these research initiatives being conducted out of Taibei, Taiwan, a total of 1702 sites have been enlisted to carry out clinical evaluations related to radiation therapy."

Answered by AI

Are there opportunities for individuals to join this trial?

"According to clinicaltrials.gov, the first posting of this trial was on July 20th 2016 and it has not been recruiting since June 16th 2022. Fortunately, there are 1756 other medical studies looking for patients at present."

Answered by AI

What is the current cap on participant enrollment for this trial?

"This trial is no longer enrolling participants. Initially posted on July 20th 2016 and last updated June 16th 2022, it has graduated to a different stage of the clinical process. If you are looking for similar studies, 1401 trials recruiting patients with brain cancer and 355 Radiation Therapy initiatives are currently accepting volunteers."

Answered by AI

What maladies are usually treated with Radiation Therapy?

"Radiation Therapy is commonly used to address malignant neoplasms, and has also been found to be a viable option for treating recurrent platinum sensitive primary peritoneal cancer, stage iv epithelial ovarian cancer after initial surgical intervention, as well as locally advanced nonsquamous non-small cell lung cancer."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Radiation Therapy in Treating Patients With Recurrent Brain Tumors Who Have Undergone Previous Radiation Therapy

2016. "Radiation Therapy in Treating Patients With Recurrent Brain Tumors Who Have Undergone Previous Radiation Therapy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02698254.

All > Brain Cancer > Brain Tumor